Business Context and Reporting Period
Company: Inovio Pharmaceuticals, Inc. (INO)
Filing Type: Form 8-K (Current Report)
Date of Report: July 29, 2026
Reporting Period: Preliminary data for the quarter ended June 30, 2026.
Key Financial Metrics
The filing provides limited financial data, focusing primarily on liquidity status as of June 30, 2026.
- Cash and Cash Equivalents: Approximately $36.7 million (preliminary, unaudited).
- Revenue, Profit, and Margins: The filing text does not provide a clear value.
- Debt and Liquidity: Only cash position is disclosed; no debt figures are provided in this report.
Material Changes
The filing does not contain comparative data against prior periods. It serves as a preliminary update on cash position rather than a comprehensive results report. No material changes in operations or financial condition are explicitly detailed beyond the cash estimate.
Guidance, Outlook, and Risks
Management Commentary: The financial data is based on preliminary unaudited information and management estimates. It is subject to completion of financial closing procedures and is not a comprehensive statement of results.
Auditor Status: Ernst & Young LLP has not audited, reviewed, or examined the preliminary data and expresses no opinion on it.
Risks and Contingencies:
- Actual results for the quarter ended June 30, 2026, may differ materially from preliminary estimates due to changes in assumptions or internal control reviews.
- Forward-looking statements are subject to risks detailed in the Company's Form 10-Q (ended March 31, 2026), Form 10-K (ended December 31, 2025), and the prospectus supplement filed on July 29, 2026.
Investor Verification Checklist
- Verify the final audited cash balance in the upcoming Form 10-Q for the quarter ended June 30, 2026.
- Review the "Risk Factors" section in the prospectus supplement filed on July 29, 2026, for updated business risks.
- Confirm the company's burn rate and runway based on the $36.7 million cash position once full quarterly expenses are reported.
- Monitor for any material changes to internal controls over financial reporting mentioned in future filings.